Entrada Therapeutics holder sells 86K shares

MPM-affiliated ten percent owners indirectly sold 86,482 TRDA common shares over three days in early September 2026.

Rhea-AI Filing Summary

Entrada Therapeutics, Inc. (TRDA) reported that investment entities affiliated with MPM BioVentures, including MPM BioVentures 2018, L.P. and related funds, sold a total of 86,482 shares of Common Stock in open-market transactions on September 1–3, 2026. Daily sales were 29,088 shares at a weighted average price of about $7.06 on September 1, 25,131 shares at about $7.19 on September 2, and 32,263 shares at about $7.17 on September 3, each within the price ranges disclosed in the notes. The shares are held across multiple MPM limited partnerships and LLCs, and each reporting person disclaims beneficial ownership except to the extent of its pecuniary interest. No Rule 10b5-1 trading plan is reported for these transactions.

Insider Trade Summary

Net Seller: 86,482 shares

Net Sell 3 txns

Insider MPM BIOVENTURES 2018, L.P., MPM BioVentures 2018 LLC, MPM BioVentures 2018 GP LLC

Role 10% Owner | 10% Owner | 10% Owner

Sold 86,482 shs ($617K)

Type	Security	Shares	Price	Value
Sale	Common Stock F8, F9, F4, F10	32,263	$7.17	$231K
Sale	Common Stock F5, F6, F4, F7	25,131	$7.19	$181K
Sale	Common Stock F1, F2, F3, F4	29,088	$7.06	$205K

Holdings After Transaction: Common Stock — 4,144,952 shares (Indirect, See Footnote)

Footnotes (10)

1. F1. The shares were sold as follows: 13,208 by MPM BioVentures 2014, L.P. ("BV 2014"), 881 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 455 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 13,556 by MPM BioVentures 2018, L.P. ("BV 2018"), 720 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 268 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.
2. F2. Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.80 to $7.15 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
3. F3. The shares are held as follows: 1,908,217 by BV 2014, 127,274 by BV 2014(B), 65,681 by AM BV2014, 1,958,433 by BV 2018, 104,089 by BV 2018(B) and 38,652 by AM BV2018.
4. F4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.
5. F5. The shares were sold as follows: 11,412 by BV 2014, 761 by BV 2014(B), 393 by AM BV2014, 11,712 by BV 2018, 622 by BV 2018(B) and 231 by AM BV2018.
6. F6. Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.9601 to $7.3273 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
7. F7. The shares are held as follows: 1,896,805 by BV 2014, 126,513 by BV 2014(B), 65,288 by AM BV2014, 1,946,721 by BV 2018, 103,467 by BV 2018(B) and 38,421 by AM BV2018.
8. F8. The shares were sold as follows: 14,650 by BV 2014, 977 by BV 2014(B), 504 by AM BV2014, 15,036 by BV 2018, 799 by BV 2018(B) and 297 by AM BV2018.
9. F9. Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0434 to $7.405 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
10. F10. The shares are held as follows: 1,882,155 by BV 2014, 125,536 by BV 2014(B), 64,784 by AM BV2014, 1,931,685 by BV 2018, 102,668 by BV 2018(B) and 38,124 by AM BV2018.

Key Figures

Total shares sold: 86,482 shares September 1, 2026 sale: 29,088 shares at about $7.06 per share September 2, 2026 sale: 25,131 shares at about $7.19 per share +3 more

6 metrics

Total shares sold 86,482 shares Aggregate open-market sales by MPM-affiliated entities on September 1–3, 2026

September 1, 2026 sale 29,088 shares at about $7.06 per share Weighted average sale price; price range $6.80–$7.15 per share

September 2, 2026 sale 25,131 shares at about $7.19 per share Weighted average sale price; price range $6.9601–$7.3273 per share

September 3, 2026 sale 32,263 shares at about $7.17 per share Weighted average sale price; price range $7.0434–$7.405 per share

Holdings BV 2014 1,882,155 shares Common stock held by MPM BioVentures 2014, L.P. after the latest reported sale

Holdings BV 2018 1,931,685 shares Common stock held by MPM BioVentures 2018, L.P. after the latest reported sale

Key Terms

weighted average sale price, beneficial ownership, pecuniary interest, ten percent owner

4 terms

weighted average sale price financial

"Price represents the weighted average sale price of the shares sold."

beneficial ownership regulatory

"Each Reporting Person disclaims beneficial ownership of the securities except"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"except to the extent of his or its respective pecuniary interest therein."

ten percent owner regulatory

"Reporting persons are indicated as a ten percent owner of the issuer."

FAQ

What insider activity did TRDA report for MPM BioVentures in this Form 4?

The filing reports that MPM-affiliated entities sold 86,482 shares of Entrada Therapeutics common stock in three open-market transactions on September 1–3, 2026, through indirect holdings in various MPM limited partnerships and LLCs.

On what dates and at what prices were TRDA shares sold by the MPM entities?

Sales occurred on September 1, 2026 (29,088 shares at a weighted average of about $7.06), September 2 (25,131 shares at about $7.19), and September 3 (32,263 shares at about $7.17), with each trade executed within the price ranges disclosed in the footnotes.

How many TRDA shares do the MPM entities report holding after these transactions?

After the reported sales, the MPM-related entities hold shares as follows: BV 2014 1,882,155; BV 2014(B) 125,536; AM BV2014 64,784; BV 2018 1,931,685; BV 2018(B) 102,668; and AM BV2018 38,124, all held indirectly through those entities.

Do the MPM reporting persons claim full beneficial ownership of their TRDA shares?

No. Each reporting person states that it disclaims beneficial ownership of the Entrada Therapeutics securities, except to the extent of its respective pecuniary interest in those shares held by the affiliated funds and entities.

Were the TRDA insider sales made under a Rule 10b5-1 trading plan?

The Form 4 indicates that no Rule 10b5-1 trading plan is reported for these transactions, meaning the document does not identify the sales as made pursuant to a pre-established trading plan under Rule 10b5-1.

Which entities actually sold the TRDA shares reported in this Form 4?

The footnotes state that shares were sold by MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, MPM BioVentures 2018, L.P., MPM BioVentures 2018(B), L.P. and MPM Asset Management Investors BV2018 LLC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 07:22 PM Accepted by SEC EDGAR 09/03/2026 - 07:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MPM BIOVENTURES 2018, L.P.

(Last) (First) (Middle)

C/O MPM BIOIMPACT

399 BOYLSTON STREET, SUITE 1100

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/01/2026		S		29,088(1)	D	$7.06(2)	4,202,346	I	See Footnote(3)(4)
Common Stock	09/02/2026		S		25,131(5)	D	$7.19(6)	4,177,215	I	See Footnote(4)(7)
Common Stock	09/03/2026		S		32,263(8)	D	$7.17(9)	4,144,952	I	See Footnote(4)(10)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

MPM BIOVENTURES 2018, L.P.

(Last) (First) (Middle)

C/O MPM BIOIMPACT

399 BOYLSTON STREET, SUITE 1100

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

MPM BioVentures 2018 LLC

(Last) (First) (Middle)

C/O MPM CAPITAL BIOIMPACT

399 BOYLSTON STREET, SUITE 1100

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

MPM BioVentures 2018 GP LLC

(Last) (First) (Middle)

C/O MPM BIOIMPACT

399 BOYLSTON STREET, SUITE 1100

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The shares were sold as follows: 13,208 by MPM BioVentures 2014, L.P. ("BV 2014"), 881 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 455 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 13,556 by MPM BioVentures 2018, L.P. ("BV 2018"), 720 by MPM BioVentures 2018 (B), L.P. ("BV 2018(B)") and 268 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin, Foley and Gadicke are managing directors of BV 2014 LLC and BV 2018 LLC.

2. Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.80 to $7.15 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

3. The shares are held as follows: 1,908,217 by BV 2014, 127,274 by BV 2014(B), 65,681 by AM BV2014, 1,958,433 by BV 2018, 104,089 by BV 2018(B) and 38,652 by AM BV2018.

4. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein.

5. The shares were sold as follows: 11,412 by BV 2014, 761 by BV 2014(B), 393 by AM BV2014, 11,712 by BV 2018, 622 by BV 2018(B) and 231 by AM BV2018.

6. Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.9601 to $7.3273 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

7. The shares are held as follows: 1,896,805 by BV 2014, 126,513 by BV 2014(B), 65,288 by AM BV2014, 1,946,721 by BV 2018, 103,467 by BV 2018(B) and 38,421 by AM BV2018.

8. The shares were sold as follows: 14,650 by BV 2014, 977 by BV 2014(B), 504 by AM BV2014, 15,036 by BV 2018, 799 by BV 2018(B) and 297 by AM BV2018.

9. Price represents the weighted average sale price of the shares sold. The sale price ranged from $7.0434 to $7.405 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

10. The shares are held as follows: 1,882,155 by BV 2014, 125,536 by BV 2014(B), 64,784 by AM BV2014, 1,931,685 by BV 2018, 102,668 by BV 2018(B) and 38,124 by AM BV2018.

Remarks:

See Form 4 for MPM BioVentures 2014, L.P for additional members of this joint filing.

	/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC	09/03/2026
	/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the managing member of MPM BioVentures 2018 GP LLC	09/03/2026
	/s/ Ansbert Gadicke, managing director of MPM BioVentures 2018 LLC, the managing member of MPM BioVentures 2018 GP LLC, the general partner of MPM BioVentures 2018, L.P.	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)